Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with 64Cu-labeled trastuzumab PET

被引:41
|
作者
Paudyal, Pramila [1 ,2 ]
Paudyal, Bishnuhari [1 ,2 ]
Hanaoka, Hirofumi
Oriuchi, Noboru [1 ,2 ]
Iida, Yashuhiko
Yoshioka, Hiroki [1 ,2 ]
Tominaga, Hideyuki [1 ,2 ]
Watanabe, Satoshi [3 ]
Watanabe, Shigeki [3 ]
Ishioka, Noriko S. [3 ]
Endo, Keigo [1 ,2 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Diagnost Radiol, Maebashi, Gunma, Japan
[2] Gunma Univ, Grad Sch Med, Dept Nucl Med, Maebashi, Gunma, Japan
[3] Japan Atom Energy Agcy, Quantum Beam Sci Directorate, Takasaki, Gunma, Japan
关键词
PHASE-II TRIAL; BREAST-CANCER; ANTIBODY; GEMCITABINE; CISPLATIN; MICE;
D O I
10.1111/j.1349-7006.2010.01480.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-small cell lung carcinomas (NSCLC) overexpress the Her2/neu gene in approximately 59% of cases. Trastuzumab, a humanized monoclonal antibody, interferes with Her2 signaling and is approved for the treatment of Her2/neu overexpressing breast cancer. However, its therapeutic use in Her2/neu overexpressing NSCLC remains obscure. The present study aimed to determine the role of 64 Cu-labeled trastuzumab positron emission tomography (PET) for non-invasive imaging of Her2/neu expression in NSCLC. Trastuzumab was conjugated with the bifunctional chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid (DOTA) and radiolabeled with Cu-64. The molecular specificity of DOTA-trastuzumab was determined in NSCLC cell lines with Her2/neu overexpression (NCI-H2170) and negative expression (NCI-H520). Imaging of Her2/neu expression was performed in NCI-H2170 tumor-bearing mice with 64 Cu-DOTA-trastuzumab PET and 64 Cu-DOTA-IgG. In vitro studies revealed specific binding of DOTA-trastuzumab in the Her2/neu positive NCI-H2170 cells, while no binding was seen in the Her2/neu negative NCI-H520 cell line. Biodistribution and PET studies revealed a significantly high accumulation of 64 CuDOTA-trastuzumab in the Her2/neu overexpressing NCI-H2170 tumor at 24 and 48 h post-injection (21.4 +/- 1.4% and 23.2 +/- 5.1% injection dose/gram (% ID/g), respectively). PET imaging of Her2/neu negative NCI-H520 tumors showed much less uptake of 64 CuDOTA- trastuzumab (4.0% ID/g). The NCI-H2170 tumor uptake of 64 Cu-DOTA-trastuzumab was significantly higher than that of 64 Cu-DOTA-IgG (P < 0.0001). 64 Cu-DOTA-trastuzumab showed a very clear image of a Her2/neu positive tumor and appeared to be effective as a PET tracer for imaging of Her2/neu gene expression in NSCLC, suggesting its potential clinical use for identifying patients that might benefit from trastuzumab-based therapy. (Cancer Sci 2010; 101: 1045-1050)
引用
收藏
页码:1045 / 1050
页数:6
相关论文
共 50 条
  • [21] Targeting HER2 in the treatment of non-small cell lung cancer
    Mar, Nataliya
    Vredenburgh, James J.
    Wasser, Jeffrey S.
    LUNG CANCER, 2015, 87 (03) : 220 - 225
  • [22] Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer
    Poposka, Biljana Ilievska
    Petrusevska, Gordana
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [23] PET Imaging of human Glioblastoma and Colorectal Cancer Xenografts Using 64Cu-Labeled D114 Antibody
    Zhou, Bin
    Wang, Hui
    Liu, Ren
    Wang, Mengzhe
    Deng, Huaifu
    Giglio, Ben
    Gill, Parkash
    Shan, Hong
    Li, Zibo
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (03)
  • [24] Hepatocyte growth factor and HER2/neu downregulate expression of apoptosis- inducing factor in non-small cell lung cancer
    Chiang, Yung-Yen
    Chow, Kuan-Chih
    Lin, Tze-Yi
    Chiang, I-Ping
    Fang, Hsing-Yuan
    ONCOLOGY REPORTS, 2014, 31 (02) : 597 - 604
  • [25] HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies
    Uy, Natalie F.
    Merkhofer, Cristina M.
    Baik, Christina S.
    CANCERS, 2022, 14 (17)
  • [26] HER2 mutations in Chinese patients with non-small cell lung cancer
    Song, Zhengbo
    Yu, Xinmin
    Shi, Zhiyong
    Zhao, Jun
    Zhang, Yiping
    ONCOTARGET, 2016, 7 (47) : 78152 - 78158
  • [27] Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
    Liu, Shengwu
    Li, Shuai
    Hai, Josephine
    Wang, Xiaoen
    Chen, Ting
    Quinn, Max M.
    Gao, Peng
    Zhang, Yanxi
    Ji, Hongbin
    Cross, Darren A. E.
    Wong, Kwok-Kin
    CLINICAL CANCER RESEARCH, 2018, 24 (11) : 2594 - 2604
  • [28] The Prognostic Significance of HER2 Overexpression in Non-small Cell Lung Cancer
    Takenaka, Masaru
    Hanagiri, Takeshi
    Shinohara, Shinji
    Kuwata, Taiji
    Chikaishi, Yasuhiro
    Oka, Soich
    Shigematsu, Yoshiki
    Nagata, Yoshika
    Shimokawa, Hidehiko
    Nakagawa, Makoto
    Uramoto, Hidetaka
    So, Tomoko
    Tanaka, Fumihiro
    ANTICANCER RESEARCH, 2011, 31 (12) : 4631 - 4636
  • [29] Molecular Characteristics of HER2 Mutations in Non-Small Cell Lung Cancer
    Wei, X.
    Gao, X.
    Zhang, X.
    Chen, Z.
    Wu, Y.
    Zhou, Q.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S848 - S849
  • [30] HER2 Mutations in Chinese Patients with Non-Small Cell Lung Cancer
    Song, Zhengbo
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S494 - S495